Skip to main content
SpringerLink
Log in

Retinoblastoma: A Journey of 60 Years

  • Chapter
  • First Online:
Intraocular Tumors

  • 513 Accesses

Abstract

Over the last 60 years, the management of retinoblastoma has been revolutionized with the advent of novel therapeutic modalities and a multi-disciplinary approach to children. Greater rates of eye salvage with reduced mortality have and are being achieved. There is now a shift towards rehabilitating vision and improving care throughout the world, not just high resource countries.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Seregard S, Lundell G, Svedberg H, Kivela T. Incidence of retinoblastoma from 1958 to 1998 in northern Europe: advantages of birth cohort analysis. Ophthalmology. 2004;11:1228–32.

    Google Scholar 

  2. Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009;93:1129–31.

    PubMed  Google Scholar 

  3. Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975-2004. Br J Ophthalmol. 2009;93:21–3.

    CAS  PubMed  Google Scholar 

  4. Ochicha O, et al. Pediatric malignancies in Kano, Northern Nigeria. World J Pediatr. 2012;8(3):215–9.

    Google Scholar 

  5. Waddell KM, et al. Improving survival of retinoblastoma in Uganada. Br J Ophthalmol. 2015;99:937–42.

    PubMed  Google Scholar 

  6. Owoeye JF, et al. Retinoblastoma—a clinic-pathological study in Ilorin, Nigeria. Afr J Health Sci. 2006;13(1–2):117–23.

    PubMed  Google Scholar 

  7. Barr RD. “Delays” in diagnosis: a misleading concept, yet providing opportunities for advancing clinical care. J Pediatr Hematol Oncol. 2014;36(3):169–72.

    PubMed  Google Scholar 

  8. Ribeiro KC, Antoneli CB. Trends in eye cancer mortality among children in Brazil, 1980-2002. Pediatr Blood Cancer. 2007;48:296–305.

    Google Scholar 

  9. Posner, et al. Lag time for retinoblastoma in the UK revisited: a retrospective analysis. BMJ Open. 2017;7:e015625. https://doi.org/10.1136/bmjopen-2016-015625.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Goddard AG, Kingston JE, Hungerford JL. Delay in diagnosis of retinoblastoma: risk factors and treatment outcome. Br J Ophthalmol. 1999;83:1320–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Butros LJ, et al. Delayed diagnosis of retinoblastoma: analysis of degree, cause and potential consequences. Pediatrics. 2002;109:E45.

    PubMed  Google Scholar 

  12. Khan AO, Al-Mesfer S. Lack of efficacy of dilated screening for retinoblastoma. J Pediatr Ophthalmol Strabismus. 2005;42:205–10.

    PubMed  Google Scholar 

  13. Kaliki S, Srinivasan V, Gupta A, et al. Clinical feature predictive of high-risk retinoblastoma in 403 Asian Indian patients: a case-control study. Ophthalmology. 2015;122:1165–72.

    PubMed  Google Scholar 

  14. Abramson DH, et al. Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for Group D retinoblastoma. PLoS One. 2016;11(1):e0146582.

    PubMed  PubMed Central  Google Scholar 

  15. Honavar SG, Singh AD. Management of advanced retinoblastoma. Ophthalmol Clin N Am. 2005;18:65–73.

    Google Scholar 

  16. Plowman PN, Pizer B, Kingston JE. Pineal parenchymal tumours: II. On the aggressive behavior of pinealoblastoma in patients with an inherited mutation of the RB1 gene. Clin Oncol (R Coll Radiol). 2004;16(4):244–7.

    CAS  Google Scholar 

  17. Bedford MA, Bedotto C, MacFaul PA. Retinoblastoma. A study of 139 cases. Br J Ophthalmol. 1971;55:19–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Albert DM. Historic review of retinoblastoma. Ophthalmology. 1987;94:654–62.

    CAS  PubMed  Google Scholar 

  19. Abramson DH. Retinoblastoma in the 20th century: past success and future challenges. Invest Ophthalmol Vis Sci. 2005;46:2684–91.

    Google Scholar 

  20. Kupfer C. Retinoblastoma treated with intravenous nitrogen mustard. Am J Ophthalmol. 1953;36:1721–3.

    CAS  PubMed  Google Scholar 

  21. Forrest AW. Tumours following radiation about the eye. Trans Am Acad Ophthalmol Otolaryngol. 1961;65:694–717.

    CAS  PubMed  Google Scholar 

  22. Abramson DH, Ellsworth RM, Zimmerman LE. Non-ocular cancer in retinoblastoma survivors. Trans Am Acad Ophthalmol Otolaryngol. 1976;81:454–7.

    CAS  Google Scholar 

  23. Wong FL, Boice JD, Abramson DH, et al. Cancer incidence after retinoblastoma radiation dose and sarcoma risk. JAMA. 1997;278:1262–7.

    CAS  PubMed  Google Scholar 

  24. MacCarthy A, et al. Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004. Br J Cancer. 2013;108:2455–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Fletcher O, et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst. 2004;96:357–63.

    PubMed  Google Scholar 

  26. Abramson DH, Frank CM. Second non-ocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology. 1998;105:573–9.

    CAS  PubMed  Google Scholar 

  27. Murphree AL. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin N Am. 2005;18:41–53.

    Google Scholar 

  28. Shields CL, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113:2276–80.

    PubMed  Google Scholar 

  29. Just diagnosed: staging. Children’s Oncology Group Website. 2011. https://www.childrensoncologygroup.org/index.php/newlydiagnosedwithretinoblastoma.

  30. Scelfo C, et al. An international survey of classification and treatment choices for Group D retinoblastoma. Int J Ophthalmol. 2017;10(6):961–7.

    PubMed  PubMed Central  Google Scholar 

  31. Finger PT, et al. AJCC cancer staging manual. New York: Springer; 2010. p. 561–8.

    Google Scholar 

  32. Mallipatna AC, Gallie BL, Che’vez-Barrios P, et al. Retinoblastoma. In: Amin MB, Edge SB, Greene F, et al., editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2017. p. 819–31.

    Google Scholar 

  33. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci. 1971;68:820–3.

    PubMed  Google Scholar 

  34. Price EA, Price K, Kolkiewicz K, et al. Spectrum of RB1 mutations identified in 403 retinoblastoma petients. J Med Genet. 2014;51:208–14.

    CAS  PubMed  Google Scholar 

  35. Munier FL, Balmer A, Van Melle G, Gailloud C. Radial asymmetry in the topography of retinoblastoma. Clues to the cell of origin. Ophthalmic Genet. 1994;15:101–6.

    CAS  PubMed  Google Scholar 

  36. De Potter P, Shields CL, Shields JA, et al. Use of the hydroxyapatite ocular implant in the pediatric population. Arch Ophthalmol. 1994;112:208–12.

    PubMed  Google Scholar 

  37. Kaste SC, Chang G, Fontanesi J, et al. Orbital development in the long-term survivors of retinoblastoma. J Clin Oncol. 1997;15:1183–9.

    CAS  PubMed  Google Scholar 

  38. Yadava U, Sachdeva P, Arora V. Myoconjunctival enucleation for enhanced implant motility. Result of a randomized prospective study. Indian J Ophthalmol. 2004;52:221–6.

    PubMed  Google Scholar 

  39. Shome D, Honavar SG, Raizada K, Raizada D. Implant and prosthesis movement after enucleation: a randomized controlled trial. Ophthalmology. 2010;117:1638–44.

    PubMed  Google Scholar 

  40. Ferris FL 3rd, Chew EY. A new era for the treatment of retinoblastoma. Arch Ophthalmol. 1996;114:1412.

    PubMed  Google Scholar 

  41. Kingston JE, Hungerford JL, Madreperla JA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1339–43.

    CAS  PubMed  Google Scholar 

  42. Fabian ID, et al. Focal laser treatment in addition to chemotherapy for retinoblastoma. Cochrane Database of Syst Rev. 2017;6:CD012366.

    Google Scholar 

  43. Gallie BL, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol. 1996;114:1321–8.

    CAS  PubMed  Google Scholar 

  44. Gombos DS, Kelly A, Coen PG, Kingston JE, Hungerford JL. Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location and age. Br J Ophthalmol. 2002;86:80–3.

    PubMed  PubMed Central  Google Scholar 

  45. Lee V, et al. Globe conserving treatment of the only eye in bilateral retinoblastoma. Br J Ophthalmol. 2003;87:1374–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Chaudhry S, Onadin Z, Sagoo MS, Reddy MA. The recognition of cavitary retinoblastoma tumours: Implications for management and genetic analysis. Retina. 2018;38:782–7. https://doi.org/10.1097/IAE.0000000000001597.

    Article  PubMed  Google Scholar 

  47. Muen WJ, et al. Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmology. 2012;119(3):611–6.

    PubMed  Google Scholar 

  48. Berry JL, et al. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer. 2013;60:688–93.

    PubMed  Google Scholar 

  49. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129:732–7.

    PubMed  Google Scholar 

  50. Susuki S, Yamane T, Mohri M, Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011;118:2081–7.

    Google Scholar 

  51. Yousef YA, Soliman SE, Astudillo PP, et al. Intra-arterial chemotherapy for retinoblastoma: a systemic review. JAMA Ophthalmol. 2016;134:584–91. https://doi.org/10.1001/jamaophthalmol.2016.0244.

    Article  PubMed  Google Scholar 

  52. Manjandavida FP, Honavar SG, Reddy VA, Khanna R. Management and outcome of retinoblastoma with vitreous seeds. Ophthalmology. 2014;121:517–24.

    PubMed  Google Scholar 

  53. Munier FL, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012;96:1078–83.

    PubMed  Google Scholar 

  54. Shields CL, et al. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol. 2014;132:319–25.

    PubMed  Google Scholar 

  55. Francis JH, et al. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology. 2015;122:1173–9.

    PubMed  Google Scholar 

  56. Munier FL. Classification and management of seeds in retinoblastoma. Ellsworth Lecture Ghent August 24th 2013. Ophthalmic Genet. 2014;35:193–207.

    PubMed  PubMed Central  Google Scholar 

  57. Smith SJ, Smith BD. Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2013;97(10):1231–6.

    PubMed  Google Scholar 

  58. Rao R, Honavar SG, Sharma V, Reddy VA. Intravitreal toptecan in the management of refractory and recurrent vitreous seeds in retinoblastoma. Br J Ophthalmol. 2017;102:490–5. https://doi.org/10.1136/bjophthalmol-2017-310641.

    Article  PubMed  Google Scholar 

  59. Fabian ID, et al. Primary intravenous chemotherapy for Group D retinoblastoma: a 13 year retrospective analysis. Br J Ophthalmol. 2017;101:82–8.

    PubMed  Google Scholar 

  60. Fabian ID, et al. Primary Enucleation for Group D retinoblastoma in the era of systemic and targeted chemotherapy: the price of retaining and eye. Br J Ophthalmol. 2017;0:1–5. https://doi.org/10.1136/bjophthalmol-2017-310624.

    Article  Google Scholar 

  61. Loepke AW, Soriano SG. An assessment of the effects of general anesthetics on developing brain structure and neurocognitive function. Anesth Analg. 2008;106:1681–707.

    PubMed  Google Scholar 

  62. Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120(7):923–31.

    PubMed  Google Scholar 

  63. Fabian ID, et al. High-risk histopathology features in primary and secondary enucleated international intraocular retinoblastoma classification Group D eyes. Ophthalmology. 2017;124:851–8.

    PubMed  Google Scholar 

  64. Abramson DH, Daniels AB, Marr BP, Francis JH, Brodie SE, Dunkel IJ, et al. Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for Group D retinoblastoma. PLoS One. 2016;11(1):e0146582.

    PubMed  PubMed Central  Google Scholar 

  65. Narang, et al. Predictors of long-term visual outcome after chemoreduction for management of intraocular retinoblastoma. Clin Exp Ophthalmol. 2012;40(7):736–42.

    PubMed  Google Scholar 

  66. Hall LS, Ceisler E, Abramson DH. Visual outcomes in children with bilateral retinoblastoma. J AAPOS. 1999;3(3):138–42.

    CAS  PubMed  Google Scholar 

  67. Dale N, et al. Developmental outcome, including setback, in young children with severe visual impairment. Dev Med Child Neurol. 2002;44(9):613–22.

    PubMed  Google Scholar 

  68. Fabian ID, et al. Long-term visual acuity, strabismus and nystagmus outcomes following multimodality treatment in Group D retinoblastoma eyes. Am J Ophthalmol. 2017;179:137–44.

    PubMed  Google Scholar 

  69. Tsimpida M, et al. Visual outcomes following intra-ophthalmic artery melphalan for patients with refractory retinoblastoma and age appropriate vision. Br J Ophthalmol. 2013;97:1464–70.

    PubMed  Google Scholar 

  70. Reddy MA, et al. Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma. BJO. 2017;101(12):1704–8. https://doi.org/10.1136/bjophthalmol-2017-310294.

    Article  Google Scholar 

  71. Hamama-Raz Y, Rot I, Buchbinder E. The coping experience of parents of a child with retinoblastoma- malignant eye cancer. J Psychosoc Oncol. 2012;30(1):21–40.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Judith Kingston Retinoblastoma Service, Royal London Hospital, Barts Health NHS Trust, London, UK

    Claire Hartnett & M. Ashwin Reddy

  2. Department of Ophthalmology, University Hospital Limerick, Limerick, Ireland

    Claire Hartnett

  3. National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK

    M. Ashwin Reddy

Authors
  1. Claire Hartnett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Ashwin Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Ashwin Reddy .

Editor information

Editors and Affiliations

  1. Sankara Nethralaya, Chennai, Tamil Nadu, India

    Vikas Khetan

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hartnett, C., Reddy, M.A. (2020). Retinoblastoma: A Journey of 60 Years. In: Khetan, V. (eds) Intraocular Tumors. Springer, Singapore. https://doi.org/10.1007/978-981-15-0395-5_19

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-0395-5_19

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-0394-8

  • Online ISBN: 978-981-15-0395-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation